Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium
暂无分享,去创建一个
[1] J. Vane,et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.
[2] M. Hamberg,et al. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides , 1976, Nature.
[3] S. Moncada,et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.
[4] J. Bény,et al. Interaction of bradykinin and des-Arg9-bradykinin with isolated pig coronary arteries: mechanical and electrophysiological events , 1987, Regulatory Peptides.
[5] J. Vane,et al. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[6] R. Busse,et al. Differential role of extra‐ and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells , 1988, British journal of pharmacology.
[7] Sadao Kimura,et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.
[8] A. Weston,et al. Acetylcholine releases endothelium‐derived hyperpolarizing factor and EDRF from rat blood vessels , 1988, British journal of pharmacology.
[9] S. Moncada,et al. Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.
[10] J. Vane,et al. Mediators and the anti-thrombotic properties of the vascular endothelium. , 1989, Annals of medicine.
[11] G. Dusting,et al. Hyperpolarization and relaxation of arterial smooth muscle caused by nitric oxide derived from the endothelium , 1990, Nature.
[12] N. Meanwell,et al. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation. , 1990, The Journal of pharmacology and experimental therapeutics.
[13] F. Murad,et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Vane,et al. Different patterns of release of endothelium‐derived relaxing factor and prostacyclin , 1992, British journal of pharmacology.
[15] E. Werner,et al. Particulate Endothelial Nitric Oxide Synthase: Requirement and Content of Tetrahydrobiopterin, FAD, and FMN , 1993 .
[16] Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring. , 1993, Journal of medicinal chemistry.
[17] S. Narumiya,et al. Cloning and expression of a cDNA for the human prostacyclin receptor , 1994, FEBS letters.
[18] S. Narumiya,et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. , 1994, Circulation.
[19] Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring. , 1994, Drug design and discovery.
[20] Y. Boie,et al. Cloning and expression of a cDNA for the human prostanoid IP receptor. , 1994, The Journal of biological chemistry.
[21] ONO-AP-500-02: a non prostanoid prostaglandin I2 mimetic with inhibitory activity against thromboxane synthase. , 1995, Advances in prostaglandin, thromboxane, and leukotriene research.
[22] Kai Yu,et al. Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.
[23] Barry M. Forman,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .
[24] Roger Fan,et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90 , 1998, Nature.
[25] J. Mitchell,et al. Cyclo‐oxygenase‐2: pharmacology, physiology, biochemistry and relevance to NSAID therapy , 1999, British journal of pharmacology.
[26] J. Morrow,et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.
[27] Margaret S. Wu,et al. Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects* , 1999, The Journal of Biological Chemistry.
[28] Y. Boie,et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. , 2000, Biochimica et biophysica acta.
[29] S. Dey,et al. PPARδ Functions as a Prostacyclin Receptor in Blastocyst Implantation , 2000, Trends in Endocrinology & Metabolism.
[30] F. Murad,et al. NO, nitrotyrosine, and cyclic GMP in signal transduction. , 2001, Medical Science Monitor.
[31] Daniel Metzger,et al. Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant mice , 2001, The Journal of cell biology.
[32] S. Kliewer,et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[33] U. Walter,et al. Taming platelets with cyclic nucleotides. , 2001, Biochemical pharmacology.
[34] R. Breyer,et al. Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.
[35] J. Salerno,et al. Nitric oxide synthases: domain structure and alignment in enzyme function and control. , 2003, Frontiers in bioscience : a journal and virtual library.
[36] T. Willson,et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity , 2003 .
[37] W. Sessa. eNOS at a glance , 2004, Journal of Cell Science.
[38] C. Francis,et al. Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes , 2004 .
[39] S. Moncada,et al. Nitric oxide and the vascular endothelium. , 2006, Handbook of experimental pharmacology.
[40] Garret A FitzGerald,et al. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. , 2006, American journal of respiratory cell and molecular biology.
[41] D. Bishop-Bailey,et al. Peroxisome proliferator-activated receptors and inflammation. , 2006, Pharmacology & therapeutics.
[42] J. Mitchell,et al. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs , 2006, Nature Reviews Drug Discovery.
[43] F. Faraci,et al. Endothelium-Derived Hyperpolarizing Factor: Where Are We Now? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[44] J. Pepper,et al. Stronger inhibition by nonsteroid anti‐inflammatory drugs of cyclooxygenase‐1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] F. Ali,et al. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] M. Montagnani,et al. Endothelin-1: the yin and yang on vascular function. , 2006, Current medicinal chemistry.
[47] Prostacyclin analogues: prevention of cardiovascular diseases. , 2006, Cardiovascular & hematological agents in medicinal chemistry.
[48] Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets , 2007, Blood.
[49] J. Mitchell,et al. Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. , 2007, American Journal of Physiology. Heart and Circulatory Physiology.
[50] B. Brüne,et al. Apoptotic cells induce arginase II in macrophages, thereby attenuating NO production , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[51] J. Mitchell,et al. Critical role of toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. , 2007, The Journal of endocrinology.
[52] J. Hwa,et al. Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. , 2007, Prostaglandins & other lipid mediators.
[53] J. Fruchart. Novel peroxisome proliferator activated receptor-alpha agonists. , 2007, The American journal of cardiology.